GlassScriptPhysician profile
Jan D Caldwell
NPI 1902262850
$3,440.06
in general payments reported to CMS, 2019-2025
20 companies · $630 in 2025
The $630 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $144 · 2022: $695 · 2023: $1,037 · 2024: $934 · 2025: $630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,542 · Education: $58.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,542.01 |
| Education | $58.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $815.62 | 2022-2025 | Cardiomems, 2nd Gen Centrimag Primary Console, Thoratec Heartmate 3 Lvas Implant Kit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $535.27 | 2021-2025 | Lifevest |
| Impulse Dynamics (USA) INC. | $403.78 | 2021-2025 | Optimizer, Optimizer |
| Novartis Pharmaceuticals Corporation | $310.51 | 2021-2023 | |
| Paragonix Technologies, INC. | $238.58 | 2023 | Sherpacool Box, Paragonix Sherpapak Cardiac Transport System, Shipper Box |
| Cvrx, INC. | $229.59 | 2024-2025 | Barostim Neo System |
| Astrazeneca Pharmaceuticals LP | $173.40 | 2022-2025 | Farxiga |
| Alnylam Pharmaceuticals INC. | $118.23 | 2022 | |
| Abbvie INC. | $99.64 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.69 | 2023-2024 | Jardiance |
| Novo Nordisk INC | $93.70 | 2024-2025 | Wegovy |
| Medtronic, INC. | $72.78 | 2022 | |
| Merck Sharp & Dohme LLC | $48.42 | 2023-2024 | Verquvo |
| Boston Scientific Corporation | $44.63 | 2024 | Watchman Flx |
| Pfizer INC. | $44.09 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $30.69 | 2024 | Repatha |
| Endotronix, INC. | $26.35 | 2024 | Cordella Pulomonary Artery Pressure Sensor |
| Kiniksa Pharmaceuticals International, Plc | $21.61 | 2024 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $20.86 | 2023 | Camzyos |
| Takeda Pharmaceuticals U.S.A., INC. | $15.62 | 2024 | Livtencity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jan Caldwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.